Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization

Cancer Cell International(2021)10.1186/s12935-021-01976-ySource: DataRank Database

Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization is a research paper published in Cancer Cell International (2021). On theSindex it has a DataRank of 1.0. It has been cited 53 times, with 32 citing works in its 1-hop citation network.

N/A

1.0DataRank · unranked

Scored on demand from live citation data

Open Access53 citations · 32 citing works in its network

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 5.87)OA: goldTopics (23)Linked Datasets (4)DataCite Reuse (4)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 59%Citation Network 41%

Base Score Contribution

0.598

From this paper's citation signal

Citation Network Contribution

0.408

From 20 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 32 citers.

Genomic Characteristics and Its Therapeutic Implications in Breast Cancer Patients with Detectable Molecular Residual Disease
Cancer Research and Treatment20233 citations24 referencesContributes 0.058
Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2
Pathology - Research and Practice202418 citations60 referencesContributes 0.049
Mismatch repair protein MLH1 suppresses replicative stress in BRCA2-deficient breast tumors
Journal of Clinical Investigation202411 citations52 referencesContributes 0.048
Special features of sarcomas developed in patients with Lynch syndrome: A systematic review
Critical Reviews in Oncology/Hematology202311 citations55 referencesContributes 0.045
Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes
International Journal of Molecular Sciences202343 citations108 referencesContributes 0.035

Authors (7)

Konstantinos Venetis ORCID,Roberto Piciotti ORCID,Marco Invernizzi ORCID,Elena Guerini‐Rocco ORCID,Svasti Haricharan ORCID

Live enrichment

PubMed:34001143 PMC:PMC8130151 OpenAlex:https://openalex.org/W3162192937

NCI NIH HHS

Grant: K22 CA229613

NCI NIH HHS

Grant: P30 CA030199

National Institutes of Health

Grant: 5K22CA229613-03

A pan-cancer role for MutL loss in inducing treatment resistance

FWCI

5.87

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://cancerci.biomedcentral.com/track/pdf/10.1186/s12935-021-01976-y

publisherhttps://cancerci.biomedcentral.com/track/pdf/10.1186/s12935-021-01976-y

publisherhttps://link.springer.com/content/pdf/10.1186/s12935-021-01976-y.pdf

publisherhttps://link.springer.com/article/10.1186/s12935-021-01976-y/fulltext.html

journalhttps://doi.org/10.1186/s12935-021-01976-y

Fields of Study

Genetic factors in colorectal cancerCancer Genomics and DiagnosticsLung Cancer Treatments and Mutations03 medical and health sciences0302 clinical medicine

Keywords

Breast cancerMedicineOncologyInternal medicineCancerBioinformaticsBiologyDNA repairMismatch repairImmunotherapyImmune CheckpointQH573-671610Neoplasms. Tumors. Oncology. Including cancer and carcinogensBreast cancer; DNA repair; Immune checkpoint; Immunotherapy; Mismatch repairReviewCytologyRC254-282

Sustainable Development Goals

SDG 2: 2. Zero hungerSDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling

10.6084/m9.figshare.16893091.v1figshare

Additional file 1 of Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling

10.6084/m9.figshare.16893091figshare

Additional file 2 of Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling

10.6084/m9.figshare.16893094.v1figshare

Additional file 2 of Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling

10.6084/m9.figshare.16893094figshare

Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (7)

Funding (3 grants)

Impact

Open Access

Topics

Linked Datasets (4)

Annotations (Europe PMC)